Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Ashish Kamat (1) , Roger Li (1) , Michael A O'Donnell (2) , Peter C Black (3) , Morgan Rouprêt (4) , James W Catto (5) , Eva Compérat (6) , Molly A Ingersoll (7) , Wim P Witjes (8) , David J Mcconkey (9) , J Alfred Witjes (10)

1 MD Anderson Cancer Center [Houston]
2 University of Iowa [Iowa City]
3 UBC - University of British Columbia
4 CHU Pitié-Salpêtrière [AP-HP]
5 Royal Hallamshire Hospital
6 CHU Tenon [AP-HP]
7 Immunobiologie des Cellules dendritiques
8 EAU Research Foundation [Arnhem]
9 Johns Hopkins University School of Medicine [Baltimore]
10 Radboud University Medical Center [Nijmegen]

Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also preventing progression and reducing deaths. However, response rates to BCG vary widely and are dependent on a multitude of factors.

Mots clés: BCG; Bladder cancer; Immunotherapy; Personalized therapy; Response prediction

Domaines: Immunologie

Ashish Kamat, Roger Li, Michael A O'Donnell, Peter C Black, Morgan Rouprêt, et al.. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.. European Urology, 2017, ⟨10.1016/j.eururo.2017.10.003⟩. ⟨pasteur-01659421⟩